Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951389 | 0.87 | TRIM24 (0.36) | HSD11B1CYP2A6TRPA1MALT1 | |
| SCHEMBL950253 | 0.81 | TRIM24 (0.36) | HSD11B1CYP2A6TRPA1MALT1 | |
| SCHEMBL951774 | 0.79 | HSD11B1 (0.35) | HSD11B1TRPA1MALT1NFE2L2MEN1 | |
| SCHEMBL950983 | 0.78 | HSD11B1 (0.35) | HSD11B1CYP2A6TRPA1MALT1NFE2L2 | |
| SCHEMBL951430 | 0.78 | CD274 (0.39) | MEN1ALDH1A1KMT2A | |
| SCHEMBL955150 | 0.77 | TRIM24 (0.38) | HSD11B1TRPA1MALT1NFE2L2TRPV1 | |
| SCHEMBL951504 | 0.77 | HSD11B1 (0.34) | HSD11B1TRPA1MALT1NFE2L2MEN1 | |
| SCHEMBL12528624 | 0.76 | TRPV1 (0.40) | HSD11B1TRPA1MALT1TRPV1 | |
| SCHEMBL950203 | 0.74 | TRPA1 (0.36) | HSD11B1CYP2A6TRPA1MALT1NFE2L2 | |
| SCHEMBL951737 | 0.74 | MYC (0.41) | TRPA1MALT1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968573-B2 | Hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-06-28 | — | — | US | disclosed |
| EP-1937664-B1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20110071291-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | IKEGAMI HIROSHI | 2011-03-24 | — | — | US | disclosed |
| US-7867949-B2 | Hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-11 | — | — | US | disclosed |
| EP-2251336-A1 | Hydrazide compounds as intermediates of pesticides | Sumitomo Chemical Company, Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20090181956-A1 | Hydrazide Compound and Pesticidal Use of the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| WO-2007043677-A9 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007043677-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071291-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | ACHE, H1-2, H1-0 | HSD11B1 1797/4885CYP2A6 377/4885TRPA1 437/4885 |
| US-20090181956-A1 | Hydrazide Compound and Pesticidal Use of the Same | ACHE, DDT, CAT | HSD11B1 651/4885CYP2A6 859/4885TRPA1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.